About the call
In line with the JPIAMR Strategic Research and Innovation Agenda, this call will focus on tackling the rising threat of antimicrobial resistance. Declining effectiveness of existing antimicrobials together with the low and insufficient number of promising new antimicrobials in the pipeline stresses the urgency to develop new protocols and innovative approaches for effective delivery and use of the already existing antimicrobials. This call aims to improve the treatment of bacterial and fungal infections (including co-infection) and/or the prevention of the emergence/spread of resistance in humans, animals or plants through the improvement of the efficacy, specificity, delivery, combinations and/or repurposing of drugs and plant protection agents.
Topic of the call
Proposals should focus on licenced antimicrobial agents (antibiotics/antifungals) or agents under pre-clinical and/or early clinical development, and should address at least one of the following topics:
- Improvement of drug/plant protection agent efficacy and/or specificity through chemical modifications (including hit to lead optimisation)
- Drug/plant protection agent repurposing;
- Optimisation of drug/plant protection agent combinations, alone or with adjunct therapies (including therapeutic vaccines);
- Design and implementation of new strategies (including optimisation of drug doses) for improved application, efficacy and delivery of single or combinations of antimicrobials;
- Design and implementation of innovative tools, including novel chemistry and/or new materials for improved application, efficacy and delivery of antimicrobials.
Proposals can focus on one or more of the three “One-Health” settings, namely:
- Human Health, and/or
- Animal Health (including wildlife, livestock, fishes, and companion animals), and/or
- Plants (including trees and crops)
The following sub-topics are out of scope of the call:
- Antiviral and antiparasitic agents
- Discovery and/or screening of new compounds, new vaccines and/or new targets
- Proposals solely aiming to develop new diagnostics or new companion diagnostics (companion diagnostics in evaluation of the antimicrobials can be examined but they should not be the main topic of the proposal.)
Participation of end-users, stakeholders and companies is encouraged.
Webinar for applicants
JPIAMR is pleased to invite researchers to a live webinar on the 25th of January 2022 presenting the call and the partner search tool. Representatives from funders participating in the call will be available to answer questions.
Read more and register to the webinar
Partner Search Tool
A match-making tool will be created for applicants, to facilitate networking and the creation of consortia.
The tool can be consulted for several purposes:
- Partner looking for project: As individual researcher or a representative of a lab or research team, searching for a project to join.
- Project looking for partner: If you want to build a consortium around an existing project and want to find partners for your project ideas.
Partner Search Tool for the call Disrupting drug resistance using innovative design
Eligibility
At least one Danish non-academia institution as co-applicant in the transnational consortium.
National guidelines section 9 for specific funding criteria
Consortia should consists of a maximum of six (6) project partners (including non-funded partners). The maximum number of partners can be increased to seven (7) if the consortium includes a company, or a partner coming from low or middle income countries, Lithuania or Poland. The budget of non-funded partners shall not exceed 30% of the total transnational project budget requested. Furthermore, consortia should always consist of a majority of project partners eligible for funding. Funding is granted for a maximum of three (3) years in accordance with national regulations and applicable legal provisions.
(14.00 CET)
